1-4 of 4
factor ix
Close
Sort by
Journal Articles

Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants

Benjamin J. Samelson-Jones, Jonathan D. Finn, Leslie J. Raffini, Elizabeth P. Merricks, Rodney M. Camire, Timothy C. Nichols, Valder R. Arruda
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1324–1332.
https://doi.org/10.1182/bloodadvances.2019000405
Published: 2021
Includes: Supplemental data
Journal Articles

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3241–3247.
https://doi.org/10.1182/bloodadvances.2019000811
Published: 2019
Includes: Supplemental data
Journal Articles

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Wojciech Jankowski, Joseph McGill, H. A. Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov, Zuben E. Sauna
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2668–2678.
https://doi.org/10.1182/bloodadvances.2019000338
Published: 2019
Includes: Supplemental data
Journal Articles

Hemophilia gene therapy comes of age

Lindsey A. George
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2591–2599.
https://doi.org/10.1182/bloodadvances.2017009878
Published: 2017